Form 4: Clene Inc. Director David J. Matlin Acquires Stock Options

Director David J. Matlin reports acquisition of stock options in Clene Inc.

Summary

• On October 2, 2024, David J. Matlin, a director of Clene Inc., acquired 4,990 stock options.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan.
• The exercise price is $4.89 per share, and the options vest immediately upon grant.
• The options expire on October 1, 2034.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard stock option grant to a director.

Positives

• The immediate vesting of the options could incentivize the director to work towards the company's success.

Industry Context

This is a standard practice for incentivizing company directors and aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotechnology industry to align their interests with shareholders.
• The vesting schedule and exercise price are typical components of such grants, often benchmarked against peer companies to ensure competitiveness.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders.

Key Dates